scholarly journals GS-5806 Inhibits Pre- to Postfusion Conformational Changes of the Respiratory Syncytial Virus Fusion Protein

2015 ◽  
Vol 59 (11) ◽  
pp. 7109-7112 ◽  
Author(s):  
Dharmaraj Samuel ◽  
Weimei Xing ◽  
Anita Niedziela-Majka ◽  
Jinny S. Wong ◽  
Magdeleine Hung ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Conformational Changes ◽  
Viral Entry ◽  
Viral Envelope ◽  
Host Cell Membrane ◽  
Virus Fusion ◽  
Molecule Inhibitor ◽  
Syncytial Virus

ABSTRACTGS-5806 is a small-molecule inhibitor of human respiratory syncytial virus fusion protein-mediated viral entry. During viral entry, the fusion protein undergoes major conformational changes, resulting in fusion of the viral envelope with the host cell membrane. This process is reproducedin vitrousing a purified, truncated respiratory syncytial virus (RSV) fusion protein. GS-5806 blocked these conformational changes, suggesting a possible mechanism for antiviral activity.

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Immunity ◽  
2021 ◽  
Author(s):  
Maryam Mukhamedova ◽  
Daniel Wrapp ◽  
Chen-Hsiang Shen ◽  
Morgan S.A. Gilman ◽  
Tracy J. Ruckwardt ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Antibody Responses ◽  
Virus Fusion ◽  
Syncytial Virus

scholarly journals Analysis of the Respiratory Syncytial Virus Fusion Protein Using Monoclonal and Polyclonal Antibodies

1986 ◽  
Vol 67 (3) ◽  
pp. 505-513 ◽  
Author(s):  
E. E. Walsh ◽  
P. J. Cote ◽  
B. F. Fernie ◽  
J. J. Schlesinger ◽  
M. W. Brandriss
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Polyclonal Antibodies ◽  
Virus Fusion ◽  
Syncytial Virus

The Design of Vaccines Based on the Shielding of Antigenic Site Ø of a Respiratory Syncytial Virus Fusion Protein Immunogen

2020 ◽  
pp. 2000714
Author(s):  
Steven J. Frey ◽  
Chad Varner ◽  
Ammar Arsiwala ◽  
Michael G. Currier ◽  
Martin L. Moore ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Antigenic Site ◽  
Virus Fusion ◽  
Syncytial Virus

scholarly journals Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice

PLoS ONE ◽  
2017 ◽  
Vol 12 (11) ◽  
pp. e0188708 ◽  
Author(s):  
Corinne Cayatte ◽  
Angie Snell Bennett ◽  
Gaurav Manohar Rajani ◽  
Leigh Hostetler ◽  
Sean K. Maynard ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Subunit Vaccine ◽  
Vaccine Candidates ◽  
Virus Fusion ◽  
Syncytial Virus ◽  
Young Mice

scholarly journals Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection

2015 ◽  
Vol 59 (8) ◽  
pp. 4889-4900 ◽  
Author(s):  
Robert Jordan ◽  
Matt Shao ◽  
Richard L. Mackman ◽  
Michel Perron ◽  
Tomas Cihlar ◽  
...  
Keyword(s):  
Viral Load ◽  
Respiratory Syncytial Virus ◽  
Structural Analog ◽  
Therapeutic Benefit ◽  
Viral Envelope ◽  
Fusion Inhibitor ◽  
Lung Pathology ◽  
Host Cell Membrane ◽  
Rsv Infection ◽  
Syncytial Virus

ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in infants. Effective treatment for RSV infection is a significant unmet medical need. While new RSV therapeutics are now in development, there are very few animal models that mimic the pathogenesis of human RSV, making it difficult to evaluate new disease interventions. Experimental infection of Holstein calves with bovine RSV (bRSV) causes a severe respiratory infection that is similar to human RSV infection, providing a relevant model for testing novel therapeutic agents. In this model, viral load is readily detected in nasal secretions by quantitative real-time PCR (qRT-PCR), and cumulative symptom scoring together with histopathology evaluations of infected tissue allow for the assessment of disease severity. The bovine RSV model was used to evaluate the antiviral activity of an RSV fusion inhibitor, GS1, which blocks virus entry by inhibiting the fusion of the viral envelope with the host cell membrane. The efficacy of GS1, a close structural analog of GS-5806 that is being developed to treat RSV infection in humans was evaluated in two randomized, blind, placebo-controlled studies in bRSV-infected calves. Intravenous administration of GS1 at 4 mg/kg of body weight/day for 7 days starting 24 h or 72 h postinoculation provided clear therapeutic benefit by reducing the viral load, disease symptom score, respiration rate, and lung pathology associated with bRSV infection. These data support the use of the bovine RSV model for evaluation of experimental therapeutics for treatment of RSV.

scholarly journals Molecular Epidemiology and Phylodynamics of the Human Respiratory Syncytial Virus Fusion Protein in Northern Taiwan

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e64012 ◽  
Author(s):  
Hsin Chi ◽  
Hsin-Fu Liu ◽  
Li-Chuan Weng ◽  
Nai-Yu Wang ◽  
Nan-Chang Chiu ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Fusion Protein ◽  
Molecular Epidemiology ◽  
Human Respiratory Syncytial Virus ◽  
Virus Fusion ◽  
Syncytial Virus ◽  
Northern Taiwan
Sign in / Sign up

Export Citation Format

Share Document